source
- AI’s role in medicine isn’t monolithic, says industry leader, urging nuanced adoptionPriya Abani, CEO of health‑tech firm AliveCor, argues that asking whether AI is good for medicine is a question with an obvious answer: it is. She says the debate has become redundant and that the…
- Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drugTarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.Fierce Biotech · 9h ago↗ source
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui